S&P 500   4,109.31
DOW   33,274.15
QQQ   320.93
MarketBeat Week in Review – 3/27 - 3/31
Where Are The Markets Going Next? (Ad)pixel
'War of the states': EV, chip makers lavished with subsidies
Gas prices increase in NJ, around nation amid higher demand
Where Are The Markets Going Next? (Ad)pixel
Lanterns and crescents: more retailers court Ramadan buyers
Shipbuilder Austal executives accused of inflating earnings
Where Are The Markets Going Next? (Ad)pixel
No more room for vroom? Paris votes on banishing e-scooters
S&P 500   4,109.31
DOW   33,274.15
QQQ   320.93
MarketBeat Week in Review – 3/27 - 3/31
Where Are The Markets Going Next? (Ad)pixel
'War of the states': EV, chip makers lavished with subsidies
Gas prices increase in NJ, around nation amid higher demand
Where Are The Markets Going Next? (Ad)pixel
Lanterns and crescents: more retailers court Ramadan buyers
Shipbuilder Austal executives accused of inflating earnings
Where Are The Markets Going Next? (Ad)pixel
No more room for vroom? Paris votes on banishing e-scooters
S&P 500   4,109.31
DOW   33,274.15
QQQ   320.93
MarketBeat Week in Review – 3/27 - 3/31
Where Are The Markets Going Next? (Ad)pixel
'War of the states': EV, chip makers lavished with subsidies
Gas prices increase in NJ, around nation amid higher demand
Where Are The Markets Going Next? (Ad)pixel
Lanterns and crescents: more retailers court Ramadan buyers
Shipbuilder Austal executives accused of inflating earnings
Where Are The Markets Going Next? (Ad)pixel
No more room for vroom? Paris votes on banishing e-scooters
S&P 500   4,109.31
DOW   33,274.15
QQQ   320.93
MarketBeat Week in Review – 3/27 - 3/31
Where Are The Markets Going Next? (Ad)pixel
'War of the states': EV, chip makers lavished with subsidies
Gas prices increase in NJ, around nation amid higher demand
Where Are The Markets Going Next? (Ad)pixel
Lanterns and crescents: more retailers court Ramadan buyers
Shipbuilder Austal executives accused of inflating earnings
Where Are The Markets Going Next? (Ad)pixel
No more room for vroom? Paris votes on banishing e-scooters
NASDAQ:ACRS

Aclaris Therapeutics - ACRS Stock Forecast, Price & News

$8.09
-0.24 (-2.88%)
(As of 03/31/2023 12:00 AM ET)
Add
Compare
Today's Range
$8.04
$8.73
50-Day Range
$7.07
$17.48
52-Week Range
$5.77
$18.96
Volume
693,032 shs
Average Volume
1.75 million shs
Market Capitalization
$539.52 million
P/E Ratio
N/A
Dividend Yield
N/A
Price Target
$32.00

Aclaris Therapeutics MarketRank™ Forecast

Analyst Rating
Buy
3.00 Rating Score
Upside/​Downside
295.6% Upside
$32.00 Price Target
Short Interest
Bearish
8.12% of Float Sold Short
Dividend Strength
N/A
Sustainability
N/A
News Sentiment
0.00mentions of Aclaris Therapeutics in the last 14 days
Based on 3 Articles This Week
Insider Trading
Selling Shares
$994,615 Sold Last Quarter
Proj. Earnings Growth
Growing
From ($1.73) to ($1.67) Per Share

Overall MarketRank

MarketRank is calculated as an average of available category scores, with extra weight given to analysis and valuation.

1.85 out of 5 stars

Medical Sector

728th out of 996 stocks

Pharmaceutical Preparations Industry

353rd out of 484 stocks


ACRS stock logo

About Aclaris Therapeutics (NASDAQ:ACRS) Stock

Aclaris Therapeutics, Inc. operates as a dermatologist-led biopharmaceutical company, which engages in identifying, developing, and commercializing novel drugs to address the needs in medical and aesthetic dermatology and immunology. It operates through the Therapeutics and Contract Research segments. The Therapeutics segment focuses on identifying, developing, and commercializing different therapies to address significant unmet needs in medical and aesthetic dermatology. The Contract Research segment provides laboratory services under contract research arrangements to pharmaceutical and biotech companies. The company was founded by Neal S. Walker, Frank Ruffo, Kamil Ali-Jackson, Christopher V. Powala, and Stuart D. Shanler in July 2012 and is headquartered in Wayne, PA.

Receive ACRS Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Aclaris Therapeutics and its competitors with MarketBeat's FREE daily newsletter.

ACRS Stock News Headlines

ACRS.O
Did You See These Trend Reversals?
Get ready for a potentially shocking and unprecedented announcement from the Fed meeting on May 3rd. This could cause many retail and industry traders to resort to drastic measures. One swift stroke could make popular assets plummet, BUT… there’s a straightforward solution to act now to protect your family and wealth. pixel
Analyst Ratings for Aclaris Therapeutics
Did You See These Trend Reversals?
Get ready for a potentially shocking and unprecedented announcement from the Fed meeting on May 3rd. This could cause many retail and industry traders to resort to drastic measures. One swift stroke could make popular assets plummet, BUT… there’s a straightforward solution to act now to protect your family and wealth. pixel
ACRS Aclaris Therapeutics, Inc.
Aclaris Therapeutics Provides 2023 Outlook
SVB Securities Keeps Their Buy Rating on Aclaris Therapeutics (ACRS)
Aclaris Therapeutics Announces Key Leadership Transitions
Aclaris Therapeutics Looks Promising on the Charts
See More Headlines
Receive ACRS Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Aclaris Therapeutics and its competitors with MarketBeat's FREE daily newsletter.

ACRS Company Calendar

Last Earnings
2/23/2023
Today
4/02/2023
Next Earnings (Estimated)
5/09/2023
Fiscal Year End
12/31/2023

Industry, Sector and Symbol

Industry
Pharmaceutical preparations
Sub-Industry
N/A
Sector
Medical
Current Symbol
NASDAQ:ACRS
Employees
72
Year Founded
2012

Price Target and Rating

Average Stock Price Forecast
$32.00
High Stock Price Forecast
$43.00
Low Stock Price Forecast
$21.00
Forecasted Upside/Downside
+295.6%
Consensus Rating
Buy
Rating Score (0-4)
3.00
Research Coverage
7 Analysts

Profitability

Net Income
$-86,910,000.00
Net Margins
-292.11%
Pretax Margin
-292.11%

Debt

Sales & Book Value

Annual Sales
$29.75 million
Book Value
$2.96 per share

Miscellaneous

Free Float
62,225,000
Market Cap
$539.52 million
Optionable
Optionable
Beta
0.60

Social Links


Key Executives

  • Douglas J. Manion
    President, Chief Executive Officer & Director
  • Kevin Balthaser
    Chief Financial Officer
  • Gail Cawkwell
    Chief Medical Officer
  • Joseph B. MonahanJoseph B. Monahan
    Chief Scientific Officer
  • James Loerop
    Chief Business Officer













ACRS Stock - Frequently Asked Questions

Should I buy or sell Aclaris Therapeutics stock right now?

7 Wall Street research analysts have issued "buy," "hold," and "sell" ratings for Aclaris Therapeutics in the last twelve months. There are currently 7 buy ratings for the stock. The consensus among Wall Street research analysts is that investors should "buy" ACRS shares.
View ACRS analyst ratings
or view top-rated stocks.

What is Aclaris Therapeutics' stock price forecast for 2023?

7 analysts have issued 1-year price objectives for Aclaris Therapeutics' shares. Their ACRS share price forecasts range from $21.00 to $43.00. On average, they predict the company's share price to reach $32.00 in the next year. This suggests a possible upside of 295.6% from the stock's current price.
View analysts price targets for ACRS
or view top-rated stocks among Wall Street analysts.

How have ACRS shares performed in 2023?

Aclaris Therapeutics' stock was trading at $15.75 at the beginning of the year. Since then, ACRS stock has decreased by 48.6% and is now trading at $8.09.
View the best growth stocks for 2023 here
.

When is Aclaris Therapeutics' next earnings date?

The company is scheduled to release its next quarterly earnings announcement on Tuesday, May 9th 2023.
View our ACRS earnings forecast
.

How were Aclaris Therapeutics' earnings last quarter?

Aclaris Therapeutics, Inc. (NASDAQ:ACRS) released its quarterly earnings results on Thursday, February, 23rd. The biotechnology company reported ($0.41) EPS for the quarter, topping analysts' consensus estimates of ($0.44) by $0.03. The biotechnology company earned $7.80 million during the quarter, compared to analysts' expectations of $1.99 million. Aclaris Therapeutics had a negative trailing twelve-month return on equity of 41.71% and a negative net margin of 292.11%. The company's revenue was up 420.0% on a year-over-year basis. During the same period last year, the firm earned ($0.37) EPS.

What is Neal Walker's approval rating as Aclaris Therapeutics' CEO?

1 employees have rated Aclaris Therapeutics Chief Executive Officer Neal Walker on Glassdoor.com. Neal Walker has an approval rating of 100% among the company's employees. This puts Neal Walker in the top 10% of approval ratings compared to other CEOs of publicly-traded companies.

What other stocks do shareholders of Aclaris Therapeutics own?
What is Aclaris Therapeutics' stock symbol?

Aclaris Therapeutics trades on the NASDAQ under the ticker symbol "ACRS."

How do I buy shares of Aclaris Therapeutics?

Shares of ACRS stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.

What is Aclaris Therapeutics' stock price today?

One share of ACRS stock can currently be purchased for approximately $8.09.

How much money does Aclaris Therapeutics make?

Aclaris Therapeutics (NASDAQ:ACRS) has a market capitalization of $539.52 million and generates $29.75 million in revenue each year. The biotechnology company earns $-86,910,000.00 in net income (profit) each year or ($1.33) on an earnings per share basis.

How can I contact Aclaris Therapeutics?

Aclaris Therapeutics' mailing address is 640 LEE ROAD SUITE 200, WAYNE PA, 19087. The official website for the company is www.aclaristx.com. The biotechnology company can be reached via phone at (484) 324-7933, via email at investors@aclaristx.com, or via fax at 484-320-2344.

This page (NASDAQ:ACRS) was last updated on 4/2/2023 by MarketBeat.com Staff